Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Closer Look At Merck's Commercial Restructuring: What Happened To India?

This article was originally published in PharmAsia News

Executive Summary

In the latest overhaul of its commercial operations, Merck shared enthusiasm about prospects in emerging markets. But it did not include India, Turkey and Poland in its list of top 10 priority markets, a change from its vision shared just four years ago

Advertisement

Related Content

Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead
On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales
Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC082871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel